Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir for hospitalized patients with COVID-19-associated severe acute respiratory infection
IRCT20200328046882N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir in coronavirus disease 2019 (COVID-19) and severe acute respiratory infection (SARI) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Started Apr 2020; status: completed.
02
Drugs
sofosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)severe acute respiratory infection (SARI)
Beyond the preview
Go deeper on IRCT20200328046882N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046882N1.